Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway
Source abstract
Abstract
Sorafenib is an oral multikinase inhibitor that has become an established therapeutic approach in advanced hepatocellular carcinoma (HCC). However, the benefit of sorafenib in clinical therapy is often affected by drug resistance. Therefore, it is important to explore the mechanisms underlying sorafenib resistance and to develop individualized therapeutic strategies for coping with this problem. In this study, we found that addition of HGF to sorafenib-treated HCC cells activated MET and re-stimulated the downstream AKT and ERK1/2 pathways. Thereby, restored sorafenib-treated HCC cells proliferation, migration and invasion ability, and rescued cells from apoptosis. In addition, we found that HGF treatment of HCC cells induced early growth response protein (EGR1) expression, which is involved in sorafenib resistance. Importantly, the HGF rescued effect in sorafenib-treated HCC cells could be abrogated by inhibiting MET activation with PHA-665752 or by downregulating EGR1 expression with small interfering RNA (siRNA). Therefore, inhibition of the HGF/MET pathway may improve response to sorafenib in HCC, and combination therapy should be further investigated.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Liver physiology and pathology · Cancer Mechanisms and Therapy · Hepatocellular Carcinoma Treatment and Prognosis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Hepatobiliary Surgery, Sun Yat-Sen University Cancer Center
Department of General Surgery, Zhuhai People's Hospital, Zhuhai Hospital of Jinan University
Zhuhai Interventional Medical Center, Zhuhai Precision Medicine Center, Zhuhai People's Hospital, Zhuhai Hospital of Jinan University
References (30)
Show source-provided references
1. 10.3322/caac.2126210.3322/caac.21262 ↗
2. 10.1634/theoncologist.11-7-79010.1634/theoncologist.11-7-790 ↗
3. 10.1097/00000658-199503000-0001210.1097/00000658-199503000-00012 ↗
4. 10.1016/S0140-6736(03)14964-110.1016/S0140-6736(03)14964-1 ↗
5. 10.1159/00048124410.1159/000481244 ↗
6. 10.1016/S1470-2045(08)70285-710.1016/S1470-2045(08)70285-7 ↗
7. Palmer DH. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:2498–2499.
8. 10.1038/nrm301210.1038/nrm3012 ↗
9. 10.1038/nrm126110.1038/nrm1261 ↗
10. 10.1126/science.114147810.1126/science.1141478 ↗
11. 10.1002/hep.2949610.1002/hep.29496 ↗
12. 10.5582/ddt.2011.v5.1.210.5582/ddt.2011.v5.1.2 ↗
13. 10.4161/15384101.2014.98803310.4161/15384101.2014.988033 ↗
14. 10.1158/1078-0432.CCR-13-262010.1158/1078-0432.CCR-13-2620 ↗
15. 10.1038/onc.2012.12710.1038/onc.2012.127 ↗
16. 10.1371/journal.pone.004271710.1371/journal.pone.0042717 ↗
17. 10.1002/hep.2877310.1002/hep.28773 ↗
18. 10.1111/liv.1252410.1111/liv.12524 ↗
19. 10.1186/s13046-015-0238-210.1186/s13046-015-0238-2 ↗
20. 10.1158/0008-5472.CAN-06-137710.1158/0008-5472.CAN-06-1377 ↗
21. 10.1016/j.canlet.2012.10.02110.1016/j.canlet.2012.10.021 ↗
22. 10.1371/journal.pone.007867510.1371/journal.pone.0078675 ↗
23. 10.1124/jpet.110.17578610.1124/jpet.110.175786 ↗
24. 10.1158/1535-7163.MCT-13-104310.1158/1535-7163.MCT-13-1043 ↗
25. 10.1038/nm90510.1038/nm905 ↗
26. 10.1002/jcp.2244510.1002/jcp.22445 ↗
27. 10.1002/jcp.2160310.1002/jcp.21603 ↗
28. 10.1016/j.cellsig.2007.01.00810.1016/j.cellsig.2007.01.008 ↗
29. 10.1158/0008-5472.CAN-14-193210.1158/0008-5472.CAN-14-1932 ↗
30. 10.1016/j.jhep.2013.09.00910.1016/j.jhep.2013.09.009 ↗